coagulation factor VII

coagulation factor VII

 Factor VII, see there.
References in periodicals archive ?
Contract awarded for event 2871/2015 recombinant coagulation factor vii assets, dust and settlement 1mg rt for parenteral use (50kui).
The increased INR values with Neoplastin R during unstable anticoagulation, such as in the initial phase of oral anticoagulation treatment, could be explained by fluctuations in coagulation factor VII (FVII) concentrations owing to the low half-life of FVII.
Use of activated recombinant coagulation factor VII in patients undergoing reconstruction surgery for traumatic fracture of pelvis or pelvis and acetabulum: a double-blind, randomized, placebo-control.
After each repast, researchers measured concentrations of coagulation factor VII (FVII), a protein that triggers production of a clotting agent in the blood.
Contract awarded for event 4098/2015 recombinant coagulation factor vii assets, dust and settlement 1mg rt for parenteral use (50 kiu).
In this model, all clotting is initiated by the combination of tissue factor and activated coagulation factor VII (FVIIa).
Contract awarded for recombinant coagulation factor vii assets, dust and settlement 1mg rt for parenteral use (50kui).
Coagulation factor VII (FVII) is a vitamin K-dependent protease that plays a key role in the initiation of the activation of the blood coagulation cascade.
Contract awarded for event 2826/2015 recombinant coagulation factor vii assets, dust and settlement 1mg rt for parenteral use (50kui).
We developed a pyrosequencing-based genotyping protocol for parallel analysis of the [beta]-fibrinogen (-455G/A and -854 G/A), prothrombin (G20210A), coagulation factor V Leiden (G1691; Arg506G1n), coagulation factor VII (-401G/T and -402 G/A), coagulation factor XIII (G163T; Val34Leu), plasminogen activator inhibitor-1 (PAI-1; -675 4G/5G), methylenetetrahydrofolate reductase (MTHFR; C677T; Ala222Val), glycoprotein IIIa (GPIIIa; C1565T; Leu33Pro; also known as PlA1/ PlA2), and endothelial nitric oxide synthase (eNOS; G894T; G1u298Asp) polymorphisms, together with the cytochrome P450 2C9 [CYP2C9*1 (wild type)], CYP2C9*2 (C430T; Cys144Arg), CYP2C9*3 (A1075C; Ile359Leu), and CYP2C9*4 (T1076C; Ile359Thr) isoforms, which modulate the effect of warfarin in antithrombotic therapy.
Pre-Clinical Safety and Prolonged Pharmacokinetic/Pharmacodynamic (PK/PD) Properties of a Recombinant Fusion Protein Linking Activated Coagulation Factor VII with Albumin (rVIIa-FP)(S.

Full browser ?